Four Companies Worth Investing In March
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy TMDX?
Source: Fool
- Axon Enterprise Growth: Axon's Q4 2025 revenue reached $797 million, a 39% year-over-year increase, with full-year revenue at $2.8 billion, marking four consecutive years of over 30% growth, indicating strong potential in the public safety sector.
- Vertiv Demand Surge: Vertiv's 2025 revenue hit $10.2 billion, up 28% year-over-year, with organic orders soaring 81%, ending the year with a backlog of $15 billion, reflecting robust demand and future growth potential in the data center market.
- TransMedics Market Dominance: TransMedics reported $605.5 million in revenue for 2025, a 37% increase, with its Organ Care System accounting for 36% of U.S. liver transplants, and guidance for 2026 suggests 20% to 25% growth, highlighting its monopoly in organ logistics.
- Fair Isaac Financial Strength: Fair Isaac's fiscal 2025 revenue was $1.99 billion, with net income of $651.9 million and a net profit margin of 32.8%, alongside a $1.5 billion stock buyback announcement, showcasing its strong market position and financial health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMDX
Wall Street analysts forecast TMDX stock price to rise
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 129.610
Low
115.00
Averages
147.80
High
170.00
Current: 129.610
Low
115.00
Averages
147.80
High
170.00
About TMDX
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TransMedics Stock Doubles, Leading Organ Transplant Market
- Market Leadership: TransMedics holds approximately 20% market share in the U.S. organ transplant sector, leveraging its innovative Organ Care System (OCS) and National OCS Program (NOP) to enhance utilization rates for hearts, lungs, and livers, demonstrating its critical role in optimizing traditional donation processes.
- Sustainable Competitive Advantage: The vertical integration of TransMedics, from R&D to logistics, creates a hard-to-replicate competitive moat, ensuring its leading position in the organ transplant industry and securing future growth potential.
- Strong Stock Performance: Since its IPO in 2019, TransMedics' stock has increased eightfold, and despite volatility, it reported a 32% sales growth rate in the latest quarter, showcasing its strong market appeal and investment value.
- Management and Market Response: Although CEO Dr. Waleed Hassanein owns only 2% of shares and the company has low employee satisfaction ratings, TransMedics' products are widely recognized for their societal value, suggesting continued investor interest in the future.
See More
TransMedics Maintains Leadership with Expanding Market Share
- Market Share Growth: TransMedics holds approximately 20% market share in the U.S. organ transplant sector, leveraging its innovative Organ Care System (OCS) and National OCS Program (NOP) to enhance organ utilization rates, which is expected to further expand its market influence.
- Strong Stock Performance: Since its IPO in 2019, TransMedics' stock has surged eightfold, with a 104% increase over the past year, demonstrating robust growth potential in the industry despite perceptions of overvaluation.
- Innovative Technology Leadership: TransMedics' OCS technology significantly improves organ preservation conditions, maintaining organ health better than traditional ice storage methods, thereby boosting organ donation utilization rates, particularly for hearts and lungs.
- Executive Leadership and Cultural Challenges: While CEO Dr. Waleed Hassanein has extensive experience in organ donation products, the company has a low employee culture rating of 3.2 stars, with only 44% of employees approving of his leadership, indicating a need to monitor internal culture's impact on future growth.
See More
Four Companies Worth Investing In March
- Axon Enterprise Growth: Axon's Q4 2025 revenue reached $797 million, a 39% year-over-year increase, with full-year revenue at $2.8 billion, marking four consecutive years of over 30% growth, indicating strong potential in the public safety sector.
- Vertiv Demand Surge: Vertiv's 2025 revenue hit $10.2 billion, up 28% year-over-year, with organic orders soaring 81%, ending the year with a backlog of $15 billion, reflecting robust demand and future growth potential in the data center market.
- TransMedics Market Dominance: TransMedics reported $605.5 million in revenue for 2025, a 37% increase, with its Organ Care System accounting for 36% of U.S. liver transplants, and guidance for 2026 suggests 20% to 25% growth, highlighting its monopoly in organ logistics.
- Fair Isaac Financial Strength: Fair Isaac's fiscal 2025 revenue was $1.99 billion, with net income of $651.9 million and a net profit margin of 32.8%, alongside a $1.5 billion stock buyback announcement, showcasing its strong market position and financial health.
See More
Analysis of Four Solid Investment Opportunities
- Axon Growth: Axon achieved $2.8 billion in revenue for fiscal year 2025, marking a 30% year-over-year increase, and set a target of $6 billion in revenue by 2028, highlighting its strong growth potential in public safety, particularly through its AI platform transformation.
- Vertiv Market Demand: Vertiv's revenue reached $10.2 billion in fiscal year 2025, up 28% year-over-year, with organic orders surging 81%, and the launch of high-density AI data center solutions in 2026 indicates its critical role in data center infrastructure.
- TransMedics Monopoly in Logistics: TransMedics reported $605.5 million in revenue for 2025, a 37% increase, with its organ transport technology accounting for 36% of U.S. liver transplants, showcasing its unique competitive advantage in the organ logistics market.
- Fair Isaac Pricing Power: Fair Isaac's revenue for fiscal year 2025 was $1.99 billion, with a net income of $651.9 million, demonstrating strong profitability and market expansion potential, especially with the introduction of its new FICO Score 10T model.
See More
TransMedics Innovates Organ Transplantation
- Innovative Storage System: TransMedics' Organ Care System (OCS) significantly enhances organ utilization rates for hearts, lungs, and livers to 98%, 97%, and 96% respectively, compared to traditional cold storage rates of 61%, 24%, and 20%, thereby increasing the number of viable organs for transplantation and improving patient outcomes.
- Strong Financial Performance: The company has experienced rapid revenue and earnings growth in recent years, indicating robust potential in the organ transplant market, which encourages investor optimism, especially as the company works to capture a larger market share.
- Transportation Network Development: To address issues related to reliance on third-party charter aircraft, TransMedics has established its own dedicated transportation network, which not only improves transport efficiency but also enhances the company's control over the logistics process, thereby reducing potential risks.
- Market Risks and Opportunities: While TransMedics faces regulatory hurdles and high maintenance costs for its transportation network, effective management of these challenges and ongoing innovation could lead to significant stock growth over the next decade, attracting increased investor interest.
See More
TransMedics Group: Revolutionizing the Organ Transplant Market
- Innovative Technology: TransMedics' Organ Care System (OCS) significantly enhances organ storage efficiency by mimicking human physiology, achieving utilization rates of 98%, 97%, and 96% for hearts, lungs, and livers respectively, compared to only 61%, 24%, and 20% with traditional cold storage, thereby reducing organ waste and providing more options for patients.
- Market Potential: With the organ transplant market expanding, TransMedics has seen rapid growth in revenue and earnings, and if it can capture a larger market share, its stock price is expected to soar significantly over the next decade, making it an attractive investment opportunity.
- Transportation Network Development: To address delays and shortages from reliance on third-party transport, TransMedics has built its own dedicated transportation network, which not only improves transport efficiency but also strengthens the company's competitive position in the organ transplant sector.
- R&D Challenges: Despite advancements in the development of the Organ Care System, the company faces regulatory hurdles and complexities in technology development, with any delays potentially negatively impacting stock prices, thus investors should closely monitor these risks.
See More
TransMedics Stock Doubles, Leading Organ Transplant Market
- Market Leadership: TransMedics holds approximately 20% market share in the U.S. organ transplant sector, leveraging its innovative Organ Care System (OCS) and National OCS Program (NOP) to enhance utilization rates for hearts, lungs, and livers, demonstrating its critical role in optimizing traditional donation processes.
- Sustainable Competitive Advantage: The vertical integration of TransMedics, from R&D to logistics, creates a hard-to-replicate competitive moat, ensuring its leading position in the organ transplant industry and securing future growth potential.
- Strong Stock Performance: Since its IPO in 2019, TransMedics' stock has increased eightfold, and despite volatility, it reported a 32% sales growth rate in the latest quarter, showcasing its strong market appeal and investment value.
- Management and Market Response: Although CEO Dr. Waleed Hassanein owns only 2% of shares and the company has low employee satisfaction ratings, TransMedics' products are widely recognized for their societal value, suggesting continued investor interest in the future.
See More
TransMedics Maintains Leadership with Expanding Market Share
- Market Share Growth: TransMedics holds approximately 20% market share in the U.S. organ transplant sector, leveraging its innovative Organ Care System (OCS) and National OCS Program (NOP) to enhance organ utilization rates, which is expected to further expand its market influence.
- Strong Stock Performance: Since its IPO in 2019, TransMedics' stock has surged eightfold, with a 104% increase over the past year, demonstrating robust growth potential in the industry despite perceptions of overvaluation.
- Innovative Technology Leadership: TransMedics' OCS technology significantly improves organ preservation conditions, maintaining organ health better than traditional ice storage methods, thereby boosting organ donation utilization rates, particularly for hearts and lungs.
- Executive Leadership and Cultural Challenges: While CEO Dr. Waleed Hassanein has extensive experience in organ donation products, the company has a low employee culture rating of 3.2 stars, with only 44% of employees approving of his leadership, indicating a need to monitor internal culture's impact on future growth.
See More
Four Companies Worth Investing In March
- Axon Enterprise Growth: Axon's Q4 2025 revenue reached $797 million, a 39% year-over-year increase, with full-year revenue at $2.8 billion, marking four consecutive years of over 30% growth, indicating strong potential in the public safety sector.
- Vertiv Demand Surge: Vertiv's 2025 revenue hit $10.2 billion, up 28% year-over-year, with organic orders soaring 81%, ending the year with a backlog of $15 billion, reflecting robust demand and future growth potential in the data center market.
- TransMedics Market Dominance: TransMedics reported $605.5 million in revenue for 2025, a 37% increase, with its Organ Care System accounting for 36% of U.S. liver transplants, and guidance for 2026 suggests 20% to 25% growth, highlighting its monopoly in organ logistics.
- Fair Isaac Financial Strength: Fair Isaac's fiscal 2025 revenue was $1.99 billion, with net income of $651.9 million and a net profit margin of 32.8%, alongside a $1.5 billion stock buyback announcement, showcasing its strong market position and financial health.
See More
Analysis of Four Solid Investment Opportunities
- Axon Growth: Axon achieved $2.8 billion in revenue for fiscal year 2025, marking a 30% year-over-year increase, and set a target of $6 billion in revenue by 2028, highlighting its strong growth potential in public safety, particularly through its AI platform transformation.
- Vertiv Market Demand: Vertiv's revenue reached $10.2 billion in fiscal year 2025, up 28% year-over-year, with organic orders surging 81%, and the launch of high-density AI data center solutions in 2026 indicates its critical role in data center infrastructure.
- TransMedics Monopoly in Logistics: TransMedics reported $605.5 million in revenue for 2025, a 37% increase, with its organ transport technology accounting for 36% of U.S. liver transplants, showcasing its unique competitive advantage in the organ logistics market.
- Fair Isaac Pricing Power: Fair Isaac's revenue for fiscal year 2025 was $1.99 billion, with a net income of $651.9 million, demonstrating strong profitability and market expansion potential, especially with the introduction of its new FICO Score 10T model.
See More
TransMedics Innovates Organ Transplantation
- Innovative Storage System: TransMedics' Organ Care System (OCS) significantly enhances organ utilization rates for hearts, lungs, and livers to 98%, 97%, and 96% respectively, compared to traditional cold storage rates of 61%, 24%, and 20%, thereby increasing the number of viable organs for transplantation and improving patient outcomes.
- Strong Financial Performance: The company has experienced rapid revenue and earnings growth in recent years, indicating robust potential in the organ transplant market, which encourages investor optimism, especially as the company works to capture a larger market share.
- Transportation Network Development: To address issues related to reliance on third-party charter aircraft, TransMedics has established its own dedicated transportation network, which not only improves transport efficiency but also enhances the company's control over the logistics process, thereby reducing potential risks.
- Market Risks and Opportunities: While TransMedics faces regulatory hurdles and high maintenance costs for its transportation network, effective management of these challenges and ongoing innovation could lead to significant stock growth over the next decade, attracting increased investor interest.
See More
TransMedics Group: Revolutionizing the Organ Transplant Market
- Innovative Technology: TransMedics' Organ Care System (OCS) significantly enhances organ storage efficiency by mimicking human physiology, achieving utilization rates of 98%, 97%, and 96% for hearts, lungs, and livers respectively, compared to only 61%, 24%, and 20% with traditional cold storage, thereby reducing organ waste and providing more options for patients.
- Market Potential: With the organ transplant market expanding, TransMedics has seen rapid growth in revenue and earnings, and if it can capture a larger market share, its stock price is expected to soar significantly over the next decade, making it an attractive investment opportunity.
- Transportation Network Development: To address delays and shortages from reliance on third-party transport, TransMedics has built its own dedicated transportation network, which not only improves transport efficiency but also strengthens the company's competitive position in the organ transplant sector.
- R&D Challenges: Despite advancements in the development of the Organ Care System, the company faces regulatory hurdles and complexities in technology development, with any delays potentially negatively impacting stock prices, thus investors should closely monitor these risks.
See More
